Log in

Relevant bibliographies by topics / GB recurrence / Journal articles

To see the other types of publications on this topic, follow the link: GB recurrence.

Journal articles on the topic 'GB recurrence'

Author: Grafiati

Published: 20 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'GB recurrence.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Sung, Min Je, Sung Yong Han, Jong Hyun Lee, et al. "Combinatorial Effects of Terpene, Chenodeoxycholic Acid, and Ursodeoxycholic Acid on Common Bile Duct Stone Recurrence and Gallbladder Stone Dissolution." Journal of Clinical Medicine 13, no. 23 (2024): 7414. https://doi.org/10.3390/jcm13237414.

Full text

Abstract:

Background: Ursodeoxycholic acid (UDCA), chenodeoxycholic acid (CDCA) plus UDCA (C&U), and terpene are widely administered to prevent common bile duct (CBD) stone recurrence and dissolve gallbladder (GB) stones. We evaluated and compared the combined effects of these agents on CBD stone recurrence and GB stone resolution. Methods: This study included patients who underwent endoscopic retrograde cholangiopancreatography (ERCP) at six referral centers, retrospectively. A total of 940 patients who underwent cholecystectomy before or after CBD stone removal by ERCP were evaluated to assess CBD

APA, Harvard, Vancouver, ISO, and other styles

2

Stadlbauer, Andreas, Ilker Eyüpoglu, Michael Buchfelder, et al. "Vascular architecture mapping for early detection of glioblastoma recurrence." Neurosurgical Focus 47, no. 6 (2019): E14. http://dx.doi.org/10.3171/2019.9.focus19613.

Full text

Abstract:

OBJECTIVETreatment failure and inevitable tumor recurrence are the main reasons for the poor prognosis of glioblastoma (GB). Gross-total resection at repeat craniotomy for GB recurrence improves patient overall survival but requires early and reliable detection. It is known, however, that even advanced MRI approaches have limited diagnostic performance for distinguishing tumor progression from pseudoprogression. The novel MRI technique of vascular architectural mapping (VAM) provides deeper insight into tumor microvascularity and neovascularization. In this study the authors evaluated the usef

APA, Harvard, Vancouver, ISO, and other styles

3

Stadlbauer, Andreas, Stefan Oberndorfer, Max Zimmermann, et al. "Physiologic MR imaging of the tumor microenvironment revealed switching of metabolic phenotype upon recurrence of glioblastoma in humans." Journal of Cerebral Blood Flow & Metabolism 40, no. 3 (2019): 528–38. http://dx.doi.org/10.1177/0271678x19827885.

Full text

Abstract:

Treating recurrent glioblastoma (GB) is one of the challenges in modern neurooncology. Hypoxia, neovascularization, and energy metabolism are of crucial importance for therapy failure and recurrence. Twenty-one patients with initially untreated GB who developed recurrence were examined with a novel MRI approach for noninvasive visualization of the tumor microenvironment (TME). Imaging biomarker information about oxygen metabolism (mitochondrial oxygen tension) and neovascularization (microvascular density and type) were fused for classification of five different TME compartments: necrosis, hyp

APA, Harvard, Vancouver, ISO, and other styles

4

Lessi, F., M. Morelli, P. Aretini, et al. "P14.01.B Isolation and characterization of circulating tumor cells in a glioblastoma case with recurrence at distance and correlation with tumor mutational status." Neuro-Oncology 24, Supplement_2 (2022): ii82. http://dx.doi.org/10.1093/neuonc/noac174.286.

Full text

Abstract:

Abstract Background Circulating Tumor Cells (CTCs) are considered to be one of the important causes of tumor recurrence and distant metastasis. For many years, glioblastoma (GB) was thought to be restricted to the brain. Nevertheless, a growing body of evidence indicates that, like many other cancers, hematogenic dissemination is a reality. The absence of a procedural uniformity in literature prompted us to develop an innovative and sensitive method to obtain CTCs in GB. Our aim is to define the genetic background of single CTCs compared with the primary GB tumor and its recurrence to assess w

APA, Harvard, Vancouver, ISO, and other styles

5

Beppu, Takaaki, Yuichi Sato, Toshiaki Sasaki, Kazunori Terasaki, and Kuniaki Ogasawara. "NI-19 Use of 11C-methionine PET for decision of discontinuation of adjuvant chemotherapy with temozolomide." Neuro-Oncology Advances 2, Supplement_3 (2020): ii14. http://dx.doi.org/10.1093/noajnl/vdaa143.062.

Full text

Abstract:

Abstract Background: The aim was to clarify whether positron emission tomography with 11C-methyl-L-methionine (met-PET) is useful to decide on discontinuation of TMZ-adjuvant therapy in patients with residual diffuse astrocytic tumor. Methods: Subjects were 44 patients with residual tumor comprising 17 with IDH1-mutant diffuse astrocytoma (DA), 13 with IDH1-mutant anaplastic astrocytoma (AA), and 14 with IDH1-wild glioblastoma (GB). All patients received TMZ-adjuvant chemotherapy (median, 12 courses), and whether to discontinue or continue TMZ-adjuvant chemotherapy was decided on the basis of

APA, Harvard, Vancouver, ISO, and other styles

6

Pettiwala, Aafrin M., Cathy Pichol-Thievend, Oceane Anezo, et al. "TMIC-76. GLIOBLASTOMA VESSEL CO-OPTION OCCURS AS A RESISTANCE MECHANISM TO CHEMORADIATION VIA INDUCTION OF A NOVEL CELL STATE." Neuro-Oncology 25, Supplement_5 (2023): v295. http://dx.doi.org/10.1093/neuonc/noad179.1141.

Full text

Abstract:

Abstract Glioblastoma (GB) is one of the deadliest types of human cancer. Despite a very aggressive treatment regime-including resection, chemo-radiation, its recurrence rate is more than 90%. Recurrence is mostly caused by highly resistant and invasive cells that spread from tumor bulk and are not removed by resection. To develop an effective therapeutic approach, we need to better understand underlying molecular and cellular mechanism driving therapy resistance and invasion in GB. To dynamically track the changes post-therapy and chemoradiation-resistant cells, we employed multiple bulk and

APA, Harvard, Vancouver, ISO, and other styles

7

Belokon, S. V., I. A. Gulidov, D. V. Gogolin, K. E. Medvedeva, S. A. Ivanov, and A. D. Kaprin. "Re-irradiation combined with bevacizumab in the treatment of glioblastoma recurrence." Siberian journal of oncology 23, no. 1 (2024): 142–54. http://dx.doi.org/10.21294/1814-4861-2024-23-1-142-154.

Full text

Abstract:

Background. Glioblastoma (GB) remains an aggressive disease with a poor prognosis. despite a comprehensive approach to the treatment of the primary disease, recurrence is almost inevitable. There is still no standard of care for GB recurrence, and many guidelines recommend treating these patients within clinical trials. There are various treatment options available. They include surgery, radiation therapy, systemic or regional chemotherapy or targeted therapy, various immunotherapy strategies, low- and medium-frequency electric fields, and their combinations. The combination of two non-invasiv

APA, Harvard, Vancouver, ISO, and other styles

8

Lee, Jae-Myeong, Bong-Wan Kim, Wook Hwan Kim, Hee-Jung Wang, and Myung Wook Kim. "Clinical Implication of Bile Spillage in Patients Undergoing Laparoscopic Cholecystectomy for Gallbladder Cancer." American Surgeon 77, no. 6 (2011): 697–701. http://dx.doi.org/10.1177/000313481107700623.

Full text

Abstract:

We determined the influence of bile spillage on recurrence and survival during laparoscopic cholecystectomy (LC) for gallbladder (GB) cancer. Among the 136 patients with GB cancer treated at Ajou University Hospital between 1994 and 2007, 28 underwent LC alone. We compared patients without bile spillage (bile spillage [-] group, n = 16) with patients who had bile spillage (bile spillage [+] group, n = 12). There was no statistical difference in stage between the groups. In the bile spillage (-) group, all patients underwent curative resection and there were two patients with locoregional recur

APA, Harvard, Vancouver, ISO, and other styles

9

Cianci, Francesca, Guido Rey, Dietmar Krex, Davide Ceresa, Paolo Malatesta, and Michele Mazzanti. "Abstract 2092: Genomic and proteomic analysis of glioblastoma recurrences during TTFields exposure." Cancer Research 84, no. 6_Supplement (2024): 2092. http://dx.doi.org/10.1158/1538-7445.am2024-2092.

Full text

Abstract:

Abstract Glioblastoma (GB) is the most aggressive type of brain tumor, and current treatments are generally ineffective in preventing recurrence. Tumor Treating Fields (TTFields) are an innovative treatment that has been shown to improve patients' life expectancy in the last two decades. TTFields therapy has an antitumoral effect that involves different mechanisms and is an optional add-on to standard maintenance temozolomide. Although TTFields therapy initially slows tumor progression, it does not prevent tumor relapse in most patients. In the present investigation, we run a genomic and prote

APA, Harvard, Vancouver, ISO, and other styles

10

Simionescu, Natalia, Miruna Nemecz, Anca-Roxana Petrovici, et al. "Microvesicles and Microvesicle-Associated microRNAs Reflect Glioblastoma Regression: Microvesicle-Associated miR-625-5p Has Biomarker Potential." International Journal of Molecular Sciences 23, no. 15 (2022): 8398. http://dx.doi.org/10.3390/ijms23158398.

Full text

Abstract:

Glioblastoma (GB) is the most aggressive and recurrent form of brain cancer in adults. We hypothesized that the identification of biomarkers such as certain microRNAs (miRNAs) and the circulating microvesicles (MVs) that transport them could be key to establishing GB progression, recurrence and therapeutic response. For this purpose, circulating MVs were isolated from the plasma of GB patients (before and after surgery) and of healthy subjects and characterized by flow cytometry. OpenArray profiling and the individual quantification of selected miRNAs in plasma and MVs was performed, followed

APA, Harvard, Vancouver, ISO, and other styles

11

Nakao, Sayumi, Michio Itabashi, Mamiko Ubukata, et al. "Age-specific prognostic factors in patients treated surgically for pulmonary metastases of colorectal cancer: A multi-institutional cumulative follow-up study." Journal of Clinical Oncology 33, no. 3_suppl (2015): 773. http://dx.doi.org/10.1200/jco.2015.33.3_suppl.773.

Full text

Abstract:

773 Background: The aim of this study was to investigate the age-specific prognostic factors for overall survival (OS) and disease-free interval (DFI) after pulmonary metastasectomy for colorectal cancer (CRC). Methods: We performed a retrospective analysis of 1,179 patients who underwent lung resection for colorectal metastases from 2001 to 2012 in 109 affiliated institutions of the Japanese Society for Cancer of the Colon and Rectum study group. The patients were divided into three groups by the age at pulmonary resection: Group A (GA) comprised of 396 patients who underwent lung resection u

APA, Harvard, Vancouver, ISO, and other styles

12

Pichol-Thievend, C., O. Anezo, A. M. Pettiwala, et al. "OS07.5.A GLIOBLASTOMA VESSEL CO-OPTION AND TRANSITION TO A RESISTANT CELL STATE ARE INDUCED BY CHEMORADIATION." Neuro-Oncology 25, Supplement_2 (2023): ii18. http://dx.doi.org/10.1093/neuonc/noad137.052.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma (GB) is one of the deadliest types of human cancer. Despite a very aggressive treatment regime, including resection of the tumor, radiation, and chemotherapy, the recurrence rate is more than 90%. Recurrence is mostly caused by the regrowth of highly invasive and resistant cells that have spread from the tumor bulk and are not removed by resection. To develop an effective therapeutic approach, we need to better understand the underlying molecular and cellular mechanisms of GB chemoradiation resistance and tumor spreading. MATERIAL AND METHODS To dynamically fol

APA, Harvard, Vancouver, ISO, and other styles

13

Centonze, Giovanni, Alessandro Mangogna, Tiziana Salviato, et al. "Gastroblastoma in Adulthood—A Rarity among Rare Cancers—A Case Report and Review of the Literature." Case Reports in Pathology 2019 (November 28, 2019): 1–6. http://dx.doi.org/10.1155/2019/4084196.

Full text

Abstract:

Gastroblastoma (GB) is a rare gastric epithelial-mesenchymal neoplasm, first described by Miettinen et al. So far, all reported cases described the tumor in children or young adults, and similarities with other childhood blastomas have been postulated. We report a case of GB in a 43-year-old patient with long follow up and no recurrence up to 100 months after surgery. So far, this is the second case of GB occurring in the adult age >40-year-old. Hence, GB should be considered in the differential diagnosis of microscopically comparable conditions in adults carrying a worse prognosis and diff

APA, Harvard, Vancouver, ISO, and other styles

14

Tan, David, Imogen Roth, Agadha Wickremesekera, et al. "Therapeutic Targeting of Cancer Stem Cells in Human Glioblastoma by Manipulating the Renin-Angiotensin System." Cells 8, no. 11 (2019): 1364. http://dx.doi.org/10.3390/cells8111364.

Full text

Abstract:

Patients with glioblastoma (GB), a highly aggressive brain tumor, have a median survival of 14.6 months following neurosurgical resection and adjuvant chemoradiotherapy. Quiescent GB cancer stem cells (CSCs) invariably cause local recurrence. These GB CSCs can be identified by embryonic stem cell markers, express components of the renin-angiotensin system (RAS) and are associated with circulating CSCs. Despite the presence of circulating CSCs, GB patients rarely develop distant metastasis outside the central nervous system. This paper reviews the current literature on GB growth inhibition in r

APA, Harvard, Vancouver, ISO, and other styles

15

Barak, M., J. Brychta, M. Hendrych, et al. "P01.10.A INVESTIGATING GLIOBLASTOMA BIOMARKERS IN THE INFILTRATION ZONE: TOPOGRAPHIC LINKS TO AN EARLY RELAPSE." Neuro-Oncology 26, Supplement_5 (2024): v32. http://dx.doi.org/10.1093/neuonc/noae144.098.

Full text

Abstract:

Abstract Glioblastoma, IDH-wildtype WHO Grade 4 (GB), is the most common primary malignant brain tumor. Despite significant advancements in surgical techniques allowing for a greater extent of resection, the use of targeted radiotherapy along with the application of novel anticancer drugs, GB remains an incurable disease with a median survival of 16 months. One of the key factors contributing to the development of therapeutic resistance and recurrence is the intratumoral heterogeneity of GB. Although surgical therapy aims at maximal safe resection with the goal of gross total tumor resection (

APA, Harvard, Vancouver, ISO, and other styles

16

Obrador, Elena, Paz Moreno-Murciano, María Oriol-Caballo, et al. "Glioblastoma Therapy: Past, Present and Future." International Journal of Molecular Sciences 25, no. 5 (2024): 2529. http://dx.doi.org/10.3390/ijms25052529.

Full text

Abstract:

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms i

APA, Harvard, Vancouver, ISO, and other styles

17

Chirica, Costin, Danisia Haba, Elena Cojocaru, et al. "One Step Forward—The Current Role of Artificial Intelligence in Glioblastoma Imaging." Life 13, no. 7 (2023): 1561. http://dx.doi.org/10.3390/life13071561.

Full text

Abstract:

Artificial intelligence (AI) is rapidly integrating into diagnostic methods across many branches of medicine. Significant progress has been made in tumor assessment using AI algorithms, and research is underway on how image manipulation can provide information with diagnostic, prognostic and treatment impacts. Glioblastoma (GB) remains the most common primary malignant brain tumor, with a median survival of 15 months. This paper presents literature data on GB imaging and the contribution of AI to the characterization and tracking of GB, as well as recurrence. Furthermore, from an imaging point

APA, Harvard, Vancouver, ISO, and other styles

18

Cho, Yoonhee, Boksoo Choi, and Hyung Sun Kim. "Rare Signet Ring Cell Carcinoma of The Gallbladder: A Case Report." American Journal of Surgery and Clinical Case Reports 08, no. 03 (2024): 01–03. http://dx.doi.org/10.47829/ajsccr.2024.8306.

Full text

Abstract:

Signet ring cell carcinoma (SRCC) is a very rare form of gallbladder (GB) cancer. SRCC is highly invasive and aggressive and mainly exhibits nonspecific symptoms of benign GB lesions; therefore, this cancer is generally diagnosed at an advanced stage. Because it is a rare disease, there are no standard treatment guidelines. Herein, we report a patient with SRCC of GB diagnosed and treated in our hospital. An 80-year-old woman visited the hospital for laparoscopic cholecystectomy for suspected gallstone causing chronic cholecystitis. A routine computed tomography scan revealed a malignancy in t

APA, Harvard, Vancouver, ISO, and other styles

19

O’Rawe, Michael, Ethan J. Kilmister, Theo Mantamadiotis, Andrew H. Kaye, Swee T. Tan, and Agadha C. Wickremesekera. "The Renin–Angiotensin System in the Tumor Microenvironment of Glioblastoma." Cancers 13, no. 16 (2021): 4004. http://dx.doi.org/10.3390/cancers13164004.

Full text

Abstract:

Glioblastoma (GB) is an aggressive primary brain tumor. Despite intensive research over the past 50 years, little advance has been made to improve the poor outcome, with an overall median survival of 14.6 months following standard treatment. Local recurrence is inevitable due to the quiescent cancer stem cells (CSCs) in GB that co-express stemness-associated markers and components of the renin–angiotensin system (RAS). The dynamic and heterogeneous tumor microenvironment (TME) plays a fundamental role in tumor development, progression, invasiveness, and therapy resistance. There is increasing

APA, Harvard, Vancouver, ISO, and other styles

20

Hamza, Mohamed Ali, Jacob Mandel, Charles A. Conrad, et al. "Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma." Journal of Clinical Oncology 31, no. 15_suppl (2013): 2042. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.2042.

Full text

Abstract:

2042 Background: Bevacizumab (BEV) is widely used for treatment of patients with recurrent glioblastoma (GB). Differences in outcome between early versus delayed BEV treatment of recurrent GB are not well defined. We examined the relationship between the time of start of BEV treatment and outcomes in patients with recurrent GB. Methods: In this retrospective chart review derived from our longitudinal database, we identified patients with recurrent GB between 2001 and 2011, who were treated with BEV alone or BEV-containing regimens. Data was analyzed to determine overall survival (OS) from time

APA, Harvard, Vancouver, ISO, and other styles

21

Chédeville, Agathe L., and Patricia A. Madureira. "The Role of Hypoxia in Glioblastoma Radiotherapy Resistance." Cancers 13, no. 3 (2021): 542. http://dx.doi.org/10.3390/cancers13030542.

Full text

Abstract:

Glioblastoma (GB) (grade IV astrocytoma) is the most malignant type of primary brain tumor with a 16 months median survival time following diagnosis. Despite increasing attention regarding the development of targeted therapies for GB that resulted in around 450 clinical trials currently undergoing, radiotherapy still remains the most clinically effective treatment for these patients. Nevertheless, radiotherapy resistance (radioresistance) is commonly observed in GB patients leading to tumor recurrence and eventually patient death. It is therefore essential to unravel the molecular mechanisms u

APA, Harvard, Vancouver, ISO, and other styles

22

Stephenson, Connor, Daniel G. McDonald, Milad Yazdani, et al. "NIMG-78. DEVELOPMENT OF A PRECLINICAL GLIOBLASTOMA MURINE MODEL FOR THE ASSESSMENT OF RADIATION NECROSIS USING DIFFUSION KURTOSIS IMAGING." Neuro-Oncology 24, Supplement_7 (2022): vii183. http://dx.doi.org/10.1093/neuonc/noac209.696.

Full text

Abstract:

Abstract Glioblastoma (GB) patients often present with either radiation-induced necrosis (RN) or develop tumor recurrence (TR). Radiologically, differentiating between these two disease states is particularly difficult, especially utilizing traditional MRI techniques. Accurately distinguishing these separate states is important, as failure to do so can ultimately lead to unnecessary surgical intervention or early cessation of appropriate radiation therapy. Currently, distinction between these pathologies is made using best clinical judgement by the neuro-oncology team. Therefore, there is a ne

APA, Harvard, Vancouver, ISO, and other styles

23

Antipina, N., A. Belyashova, G. Pavlova, et al. "P02.02 Modeling of response to irradiation in recurrence glioblastoma’s cells culture." Neuro-Oncology 23, Supplement_2 (2021): ii17. http://dx.doi.org/10.1093/neuonc/noab180.055.

Full text

Abstract:

Abstract BACKGROUND Radiosensitivity of glioblastoma (GB) cells of local relapses may be markedly different from the primary tumor. Optimal doses and regimes of re-irradiation GB recurrence is not determined yet. MATERIAL AND METHODS GO1 primary GB cell culture was obtained during removal of a recurrent tumor after combined treatment, including irradiation of the surgical bed. Сell’s culture was irradiated by photon beams with energy 6 MeV and dose rate 600 MU/min. Irradiation performed in 1, 3 and 5 fractions, by 10 different doses for each regime. The dose range was determined experimentally

APA, Harvard, Vancouver, ISO, and other styles

24

Akhunbay-Fudge, Christopher Yusuf, Kevin Critchley, Ryan Mathew, and Heiko Wurdak. "CCRG-04. AUTOMATED REAL TIME TRACKING OF GLIOBLASTOMA CELL CYCLE TRANSITIONS IN ASSEMBLOIDS LINKS G2 CELLS TO INFILTRATION." Neuro-Oncology 25, Supplement_5 (2023): v39. http://dx.doi.org/10.1093/neuonc/noad179.0153.

Full text

Abstract:

Abstract Glioblastoma (GB) is the most aggressive primary brain tumour in adults associated with survival rates below 5% despite treatment. Tumour repopulating residual cells in the surgical cavity resist treatment due to their molecular heterogeneity. Single-cell transcriptomic studies have linked GB heterogeneity to the cell cycle; however, it remains unclear to what extent cell cycle states affect the infiltrative capacity of GB. The “go or grow” paradigm predicts that migration and proliferation are separate spatiotemporal events. We used a brain tumour-cerebral organoid (assembloid) appro

APA, Harvard, Vancouver, ISO, and other styles

25

Wang, Xiaowen, Matias Bustos, Xiaoqing Zhang та ін. "Downregulation of the Ubiquitin-E3 Ligase RNF123 Promotes Upregulation of the NF-κB1 Target SerpinE1 in Aggressive Glioblastoma Tumors". Cancers 12, № 5 (2020): 1081. http://dx.doi.org/10.3390/cancers12051081.

Full text

Abstract:

This study examined the role of the ubiquitin E3-ligase RNF123 in modulating downstream NF-κB1 targets in glioblastoma (GB) tumor progression. Our findings revealed an oncogenic pathway (miR-155-5p-RNF123-NF-κB1-p50-SerpinE1) that may represent a new therapeutic target pathway for GB patients with isocitrate dehydrogenase 1 and 2 (IDH) WT (wild type). Mechanistically, we demonstrated that RNF123 is downregulated in IDH WT GB patients and leads to the reduction of p50 levels. RNA-sequencing, reverse-phase protein arrays, and in vitro functional assays on IDH WT GB cell lines with RNF123 overexp

APA, Harvard, Vancouver, ISO, and other styles

26

Lessi, Francesca, Sara Franceschi, Mariangela Morelli, et al. "Single-Cell Molecular Characterization to Partition the Human Glioblastoma Tumor Microenvironment Genetic Background." Cells 11, no. 7 (2022): 1127. http://dx.doi.org/10.3390/cells11071127.

Full text

Abstract:

Background: Glioblastoma (GB) is a devastating primary brain malignancy. The recurrence of GB is inevitable despite the standard treatment of surgery, chemotherapy, and radiation, and the median survival is limited to around 15 months. The barriers to treatment include the complex interactions among the different cellular components inhabiting the tumor microenvironment. The complex heterogeneous nature of GB cells is helped by the local inflammatory tumor microenvironment, which mostly induces tumor aggressiveness and drug resistance. Methods: By using fluorescent multiple labeling and a DEPA

APA, Harvard, Vancouver, ISO, and other styles

27

Attia, Noha, Mohamed Mashal, Sudhakar Pemminati, et al. "Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies." Cells 11, no. 1 (2021): 116. http://dx.doi.org/10.3390/cells11010116.

Full text

Abstract:

Glioblastoma (GB), an aggressive primary tumor of the central nervous system, represents about 60% of all adult primary brain tumors. It is notorious for its extremely low (~5%) 5-year survival rate which signals the unsatisfactory results of the standard protocol for GB therapy. This issue has become, over time, the impetus for the discipline of bringing novel therapeutics to the surface and challenging them so they can be improved. The cell-based approach in treating GB found its way to clinical trials thanks to a marvelous number of preclinical studies that probed various types of cells aim

APA, Harvard, Vancouver, ISO, and other styles

28

Patrón, Lilian A., Helen Yeoman, Sydney Wilson, et al. "Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma." Biomedicines 12, no. 2 (2024): 406. http://dx.doi.org/10.3390/biomedicines12020406.

Full text

Abstract:

Glioblastoma (GB) is the most lethal brain cancer in adults, with a 5-year survival rate of 5%. The standard of care for GB includes maximally safe surgical resection, radiation, and temozolomide (TMZ) therapy, but tumor recurrence is inevitable in most GB patients. Here, we describe the development of a blood–brain barrier (BBB)-penetrant tubulin destabilizer, RGN3067, for the treatment of GB. RGN3067 shows good oral bioavailability and achieves high concentrations in rodent brains after oral dosing (Cmax of 7807 ng/mL (20 μM), Tmax at 2 h). RGN3067 binds the colchicine binding site of tubuli

APA, Harvard, Vancouver, ISO, and other styles

29

Lavielle, S., G. Delrot, M. Lemaitre, et al. "P06.12.B Microbiota-gut-brain axis in glioblastoma development and therapeutic resistance." Neuro-Oncology 26, Supplement_5 (2024): v46. http://dx.doi.org/10.1093/neuonc/noae144.149.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma (GB) is the most common subtype of glioma in adults. Despite treatment through tumor resection associated with chemo and radiotherapies, this cancer still has a very poor prognosis. Factors contributing to etiology, pathogenesis, or treatment resistance are not well known. The significance of understanding the microbiome-gut-brain axis (MGBA) in GB, a topic that has been recently shown to be crucial in several neurodegenerative diseases, cannot be overstated. Therefore, our project aims to understand how modulation of gut physiopathology (i.e., gut inflammation

APA, Harvard, Vancouver, ISO, and other styles

30

Lam, Jeff Y. L., Renuka Chintapalli, Dorothea Boeken, et al. "1045 Detection of P53 Aggregates for Plasma-Based Diagnosis and Monitoring of Glioblastoma." Neurosurgery 71, Supplement_1 (2025): 144. https://doi.org/10.1227/neu.0000000000003360_1045.

Full text

Abstract:

INTRODUCTION: Although ordinarily a pivotal tumour-suppressor, p53 can form amyloid aggregates that lose tumour-suppressing functions and exert tumour-promoting activities. Detection of p53 aggregates in liquid biopsies may be a more cost-effective alternative for diagnosis, monitoring and prognostication of glioblastoma (GB) that avoids the logistical challenges of MRI. We have previously developed a novel ultrasensitive immunoassay based on the single-molecule array technology (SiMoA) for detecting p53 aggregates in plasma. METHODS: Plasma samples were collected intraoperatively from newly d

APA, Harvard, Vancouver, ISO, and other styles

31

Comas Antón, S., S. Moreno, M. Antelo, et al. "P11.30.A LONG-TERM SURVIVING GLIOBLASTOMA. CLINICAL, MOLECULAR AND SURVIVAL ANALYSES." Neuro-Oncology 25, Supplement_2 (2023): ii80. http://dx.doi.org/10.1093/neuonc/noad137.264.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma (GB) has a poor prognosis with median overall survival of 12-14 months. According to literature, patients surviving more than two years has progressively increased since 2005 and represent approximately 18% of this population, being considered long-term survivors (LTS). The aim of this study is to retrospectively analyze GB LTS treated in our Neurooncology Unit. MATERIAL AND METHODS From December 2009 to March 2021, 49 GB LTS patients were identified in our oncology data base, representing 21,7% of GB patients electronically registered during the same period. P

APA, Harvard, Vancouver, ISO, and other styles

32

Bourmeau, G., O. Anezo, A. Ballestin, C. Pichol-Thievend, J. Reveilles, and G. Seano. "OS07.7.A GLIOBLASTOMA HYBRID CELL STATE CONVEYS RESISTANCE TO CONVENTIONAL THERAPIES." Neuro-Oncology 25, Supplement_2 (2023): ii18—ii19. http://dx.doi.org/10.1093/neuonc/noad137.054.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma (GB) is a deadly disease and no therapeutic improvements have been made in the last 20 years. High phenotypic plasticity has been recognized as a major obstacle to the efficient treatment of GB. Single-cell sequencing revealed the coexistence of four different cell states within the same tumor. The transition from one subtype (or state) to another, such as from proneural (PN) to mesenchymal (MES), has been suggested as a mechanism for resistance to therapies. However, there is no prognostic value of the current GB states for patients, meaning that mechanisms of

APA, Harvard, Vancouver, ISO, and other styles

33

Morelli, M., F. Lessi, M. Giacomarra, et al. "P17.16.B INVESTIGATION OF REGORAFENIB TUMOR SENSITIVITY AND UNDERLYING TREATMENT INDUCED MOLECULAR MECHANISMS IN GLIOBLASTOMA RECURRENT TUMORS." Neuro-Oncology 25, Supplement_2 (2023): ii120—ii121. http://dx.doi.org/10.1093/neuonc/noad137.406.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma (GB) is the most aggressive brain malignant tumor with a highly unfavorable prognosis. Maximal surgery resection, temozolomide chemotherapy (TMZ), and radiotherapy (RT), currently remain the best treatment option. Recently the phase II REGOMA clinical trial, has shown that regorafenib (REGO), a multikinase inhibitor that targets angiogenic, stromal and oncogenic tyrosine kinase receptors, significantly improves survival in GB patients.The aim of this study was to investigate Regorafenib tumor sensitivity and underlying molecular mechanisms in GB recurrent tumor

APA, Harvard, Vancouver, ISO, and other styles

34

Lin, Chao-Qun, and Lu-Kui Chen. "Effect of differential hypoxia-related gene expression on glioblastoma." Journal of International Medical Research 49, no. 5 (2021): 030006052110137. http://dx.doi.org/10.1177/03000605211013774.

Full text

Abstract:

Objective Glioblastoma (GB) is a refractory malignancy with a high rate of recurrence and treatment resistance. Hypoxia-related genes are promising prognostic indicators for GB, so we herein developed a reliable hypoxia-related gene risk scoring model to predict the prognosis of patients with GB. Method Gene expression profiles and corresponding clinicopathological features of patients with GB were obtained from the Cancer Genome Atlas (TCGA; n = 160) and Gene Expression Omnibus (GEO) GSE7696 (n = 80) databases. Univariate and multivariate Cox regression analyses of differentially expressed hy

APA, Harvard, Vancouver, ISO, and other styles

35

Zimmer, Niklas, Emily R. Trzeciak, Andreas Müller, et al. "Nuclear Glycoprotein A Repetitions Predominant (GARP) Is a Common Trait of Glioblastoma Stem-like Cells and Correlates with Poor Survival in Glioblastoma Patients." Cancers 15, no. 24 (2023): 5711. http://dx.doi.org/10.3390/cancers15245711.

Full text

Abstract:

Glioblastoma (GB) is notoriously resistant to therapy. GB genesis and progression are driven by glioblastoma stem-like cells (GSCs). One goal for improving treatment efficacy and patient outcomes is targeting GSCs. Currently, there are no universal markers for GSCs. Glycoprotein A repetitions predominant (GARP), an anti-inflammatory protein expressed by activated regulatory T cells, was identified as a possible marker for GSCs. This study evaluated GARP for the detection of human GSCs utilizing a multidimensional experimental design that replicated several features of GB: (1) intratumoral hete

APA, Harvard, Vancouver, ISO, and other styles

36

Cardoso, Ana M., Catarina M. Morais, Frederico Pena, et al. "Differentiation of glioblastoma stem cells promoted by miR-128 or miR-302a overexpression enhances senescence-associated cytotoxicity of axitinib." Human Molecular Genetics 30, no. 3-4 (2021): 160–71. http://dx.doi.org/10.1093/hmg/ddab011.

Full text

Abstract:

Abstract Despite the intense global efforts towards an effective treatment of glioblastoma (GB), current therapeutic options are unsatisfactory with a median survival time of 12–15 months after diagnosis, which has not improved significantly over more than a decade. The high tumoral heterogeneity confers resistance to therapies, which has hindered a successful clinical outcome, GB remaining among the deadliest cancers. A hallmark of GB is its high recurrence rate, which has been attributed to the presence of a small subpopulation of tumor cells called GB stem-like cells (GSC). In the present w

APA, Harvard, Vancouver, ISO, and other styles

37

Jacobo, Javier A., Jorge Aristizabal, Nicolle Wagner-Gutiérrez, et al. "Glioblastoma with leptomeningeal dissemination, symptomatic intramedullary extension, and bone marrow metastases." Medicina 46, no. 2 (2024): 626–35. https://doi.org/10.56050/01205498.2387.

Full text

Abstract:

Glioblastoma (GB) is the most common primary Central Nervous System (CNS) tumor and the most malignant of the glial neoplasm; despite its aggressive behavior, metastases are rarely seen. The most common form of metastasis is leptomeningeal dissemination, which can be present in almost 15-35% of the patients, though symptomatic spinal cord invasion is far less common (1.6%), and extra neural metastases are an atypical event (0.2-3%). Here, we present the case of a 36-year-old patient with primary GB who developed leptomeningeal dissemination, intramedullary extension, and multiple extra neural

APA, Harvard, Vancouver, ISO, and other styles

38

Clavreul, Anne, Lila Autier, Jean-Michel Lemée, et al. "Management of Recurrent Glioblastomas: What Can We Learn from the French Glioblastoma Biobank?" Cancers 14, no. 22 (2022): 5510. http://dx.doi.org/10.3390/cancers14225510.

Full text

Abstract:

Safe maximal resection followed by radiotherapy plus concomitant and adjuvant temozolomide (TMZ) is universally accepted as the first-line treatment for glioblastoma (GB), but no standard of care has yet been defined for managing recurrent GB (rGB). We used the French GB biobank (FGB) to evaluate the second-line options currently used, with a view to defining the optimal approach and future directions in GB research. We retrospectively analyzed data for 338 patients with de novo isocitrate dehydrogenase (IDH)-wildtype GB recurring after TMZ chemoradiotherapy. Cox proportional hazards models an

APA, Harvard, Vancouver, ISO, and other styles

39

Bynoe, Margaret S. "Glioblastoma usurps host extracellular adenosine to circumvent host anti-tumor Responses." Journal of Immunology 198, no. 1_Supplement (2017): 76.17. http://dx.doi.org/10.4049/jimmunol.198.supp.76.17.

Full text

Abstract:

Abstract Glioblastoma (GB) is the most aggressive, fatal, and least successfully treated of all solid brain tumors due to its high capacity to proliferate and extreme chemoresistance. Treatment for GB patients is managed with multimodal therapies including surgical resection (if possible), radiotherapy and chemotherapy with temozolomide (one of the few drugs shown to have some effect). Despite this, patient survival ranges between 6–18 months. Because GB is highly infiltrative, it often invades normal brain tissue, sometimes preventing surgical resection, which inevitably leads to recurrence.

APA, Harvard, Vancouver, ISO, and other styles

40

Vilarino, Noelia, Neus Martinez-Bosch, Carmen Balana, et al. "Galectin-1 (Gal-1) expression as a prognostic factor in patients with newly diagnosed glioblastoma (GB) treated with Stupp regimen (GLIOCAT study)." Journal of Clinical Oncology 35, no. 15_suppl (2017): e13526-e13526. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e13526.

Full text

Abstract:

e13526 Background: Gal-1 is a β-galactoside binding protein that plays an important role in cancer, promoting cell invasion, proliferation, migration, angiogenesis and evasion of the immune response. Gal-1 is involved in glioma progression and is related to tumor grade and poor clinical outcome. Gal-1 has been implicated in resistance to chemotherapy and as a potential mediator of resistance to anti-VEGF therapy. The aim of our study was to evaluate the prognostic significance of Gal-1 in a homogenous cohort of GB patients and to analyze its potential predictive value of response to bevacizuma

APA, Harvard, Vancouver, ISO, and other styles

41

Lee, Sang Hun, Yong Mi Seol, and Dong Uk Kim. "Preoperative risk factors related to relapse-free survival after R0 resection of gallbladder cancer." Journal of Clinical Oncology 42, no. 3_suppl (2024): 566. http://dx.doi.org/10.1200/jco.2024.42.3_suppl.566.

Full text

Abstract:

566 Background: Gallbladder (GB) cancer shows high prevalence in South Korea, and tends to be fatal. In surgically fit patients, radical resection aiming R0 margin combined with lymphadenectomy is the mainstay of curative-intent therapy. In spite of R0 resection, however, high recurrence rate is observed in GB cancer, demanding a need to find out risk factors related to recurrence after surgery. Methods: This is a single center, retrospective cohort study conducted on 148 patients with GB cancer who underwent R0 resection between January 1st, 2014 and December 31st, 2019. Several variables wer

APA, Harvard, Vancouver, ISO, and other styles

42

Lucas Calduch, A., M. Macià Garau, S. Villà Freixa, et al. "P17.09.B REIRRADIATION AS A SALVAGE THERAPY FOR LOCAL GLIOBLASTOMA RECURRENCE." Neuro-Oncology 25, Supplement_2 (2023): ii118—ii119. http://dx.doi.org/10.1093/neuonc/noad137.399.

Full text

Abstract:

Abstract BACKGROUND There is a lack of successful strategies to treat glioblastoma (GB) recurrences. Reirradiation is one of them, but it only can be considered in a few patients with localized relapses. This review aims to analyse the role of reirradiation in this setting and the management difficulties associated with this strategy. MATERIAL AND METHODS We have retrospectively reviewed the outcome of GB patients treated with surgery and the standard Stupp regimen, that have received stereotactic radiotherapy (RT) at the time of a local in-field relapse in our centre, during the period from 2

APA, Harvard, Vancouver, ISO, and other styles

43

Gogolin, D. V., I. A. Gulidov, S. V. Belokon’, and S. N. Koryakin. "Radiation therapy with focal dose escalation in the treatment of glioblastoma." P.A. Herzen Journal of Oncology 14, no. 2 (2025): 64. https://doi.org/10.17116/onkolog20251402164.

Full text

Abstract:

Glioblastoma (GB) is one of the most frequent and aggressive primary tumor of the central nervous system, occurring mostly in elderly individuals and having an unfavorable prognosis in terms of high recurrence risks and low survival rates. The management of GB today is based on a comprehensive approach, of which radiation therapy (RT) is an integral part. In the era of temozolomide (TMZ), due to its radiosensitizing properties, the escalation of total dose (TD) above 60 Gy by EQD2 (equivalent dose in fractions of 2 Gy) through different techniques is an area of active research. Due to the diff

APA, Harvard, Vancouver, ISO, and other styles

44

Hervás-Corpión, Irati, Jorge Navarro-Calvo, Paula Martín-Climent, et al. "Defining a Correlative Transcriptional Signature Associated with Bulk Histone H3 Acetylation Levels in Adult Glioblastomas." Cells 12, no. 3 (2023): 374. http://dx.doi.org/10.3390/cells12030374.

Full text

Abstract:

Glioblastoma (GB) is the most prevalent primary brain cancer and the most aggressive form of glioma because of its poor prognosis and high recurrence. To confirm the importance of epigenetics in glioma, we explored The Cancer Gene Atlas (TCGA) database and we found that several histone/DNA modifications and chromatin remodeling factors were affected at transcriptional and genetic levels in GB compared to lower-grade gliomas. We associated these alterations in our own cohort of study with a significant reduction in the bulk levels of acetylated lysines 9 and 14 of histone H3 in high-grade compa

APA, Harvard, Vancouver, ISO, and other styles

45

Sun, Xuheng, Yijun WANG, and Yingbin Liu. "Construction and validation of the prognostic model for patients with gallbladder neuroendocrine neoplasm-based a nationwide retrospective registry study." Journal of Clinical Oncology 40, no. 16_suppl (2022): e16140-e16140. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e16140.

Full text

Abstract:

e16140 Background: Gallbladder neuroendocrine neoplasm (GB-NEN) is an extremely rare type of gallbladder neoplasm and the prognosis of patients with GB-NENs varies widely. The focus of this study was to construct and validate a prognostic model of GB-NENs based on the data from a nationwide retrospective multicenter registry cohort. Methods: The Chinese Research Group of Gallbladder Cancer (CRGGC) study is a multicenter retrospective registry cohort study reviewing the electronic medical records from 76 tertiary and secondary hospitals across 28 provinces in China. We assembled patients with G

APA, Harvard, Vancouver, ISO, and other styles

46

Todkar, Sampatti Sambhaji, and Lagdir Appasaheb Gaikwad. "Outcome of suspected H1N1 influenza cases admitted in tertiary care Govt. Hospital Solapur, Maharashtra." Indian Journal of Medical Sciences 69, no. 1 (2017): 6. http://dx.doi.org/10.18203/issn.0019-5359.indianjmedsci20170482.

Full text

Abstract:

<span class="ABS_Bold-Italic" lang="en-GB">Introduction:</span><span> Influenza (H1N1) is very sensitive and newly emerged pandemic. Influenza (H1N1) pandemics are caused by new influenza viruses that have recently adapted to humans and resemble major natural disasters both in terms of recurrence and magnitude. </span><span class="ABS_Bold-Italic" lang="en-GB">Aims and Objectives:</span><span> To study the outcome and epidemiological factors of suspected H1N1 influenza cases. </span><span class="ABS_Bold-Italic" lang="en-GB">Study Design:&l

APA, Harvard, Vancouver, ISO, and other styles

47

Mann, Anmol, Nur Safa, Emma Martell, et al. "BSCI-07 ACETYL-AMANTADINE AS A DIAGNOSTIC BIOMARKER IN PATIENTS WITH GLIOBLASTOMA." Neuro-Oncology Advances 4, Supplement_1 (2022): i2. http://dx.doi.org/10.1093/noajnl/vdac078.007.

Full text

Abstract:

Abstract AIM Glioblastoma (GB) is the most common malignant primary brain tumor in adults, with a prognosis as poor as 12-15 months with standard treatment. Spermidine/spermine N1-acetyltransferase (SAT1) is a rate limiting enzyme in polyamine metabolism and has been reported to be upregulated in various cancers, including GB. Amantadine is a Health Canada approved drug that is acetylated by SAT1. We established a clinical trial in GB patients to determine if plasma and urine acetyl amantadine (Ac-Am) can be used to measure SAT1 activity and whether levels correlate with their tumor burden. ME

APA, Harvard, Vancouver, ISO, and other styles

48

Sokolov, Dmitry K., Oleg B. Shevelev, Anna S. Khotskina, et al. "Dexamethasone Inhibits Heparan Sulfate Biosynthetic System and Decreases Heparan Sulfate Content in Orthotopic Glioblastoma Tumors in Mice." International Journal of Molecular Sciences 24, no. 12 (2023): 10243. http://dx.doi.org/10.3390/ijms241210243.

Full text

Abstract:

Glioblastoma (GB) is an aggressive cancer with a high probability of recurrence, despite active chemoradiotherapy with temozolomide (TMZ) and dexamethasone (DXM). These systemic drugs affect the glycosylated components of brain tissue involved in GB development; however, their effects on heparan sulfate (HS) remain unknown. Here, we used an animal model of GB relapse in which SCID mice first received TMZ and/or DXM (simulating postoperative treatment) with a subsequent inoculation of U87 human GB cells. Control, peritumor and U87 xenograft tissues were investigated for HS content, HS biosynthe

APA, Harvard, Vancouver, ISO, and other styles

49

Kurz, Sabine K., and Matthias J. Reddehase. "Patchwork Pattern of Transcriptional Reactivation in the Lungs Indicates Sequential Checkpoints in the Transition from Murine Cytomegalovirus Latency to Recurrence." Journal of Virology 73, no. 10 (1999): 8612–22. http://dx.doi.org/10.1128/jvi.73.10.8612-8622.1999.

Full text

Abstract:

ABSTRACT The lungs are a significant organ site of murine cytomegalovirus (mCMV) latency. We have shown that activity of the major immediate-early promoter (MIEP), which drives the transcription from the ie1-ie3 transcription unit, does not inevitably initiate the productive cycle (S. K. Kurz, M. Rapp, H.-P. Steffens, N. K. A. Grzimek, S. Schmalz, and M. J. Reddehase, J. Virol. 73:482–494, 1999). Thus, even though MIEP activity governed by the MIEP-enhancer is unquestionably the first condition for recurrence, regulation of the enhancer by transcription factors is not the only mechanism contro

APA, Harvard, Vancouver, ISO, and other styles

50

Chernov, Alexandr, Irina Baldueva, Tatyana Nekhaeva, Elvira Galimova, Diana Alaverdian, and Olga Shamova. "The molecular mechanisms of multidrug resistance of human glioblastomas." Problems in oncology 67, no. 1 (2021): 20–28. http://dx.doi.org/10.37469/0507-3758-2021-67-1-20-28.

Full text

Abstract:

In review discusses the phenomenon of drug resistance of GB in the context of the expression of ABC family transporter proteins and the processes of proliferation, angiogenesis, recurrence and death. The emphasis is on the identifying for molecular targets among growth factors, receptors, signal transduction proteins, microRNAs, transcription factors, proto-oncogenes, tumor suppressor genes and their polymorphic variants (SNPs) for the development and creation of targeted anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!